WO2007073096A1 - Anti-gastritis and anti-ulcer agent containing momordicae semen extract and momordica saponin i isolated from the same - Google Patents

Anti-gastritis and anti-ulcer agent containing momordicae semen extract and momordica saponin i isolated from the same Download PDF

Info

Publication number
WO2007073096A1
WO2007073096A1 PCT/KR2006/005603 KR2006005603W WO2007073096A1 WO 2007073096 A1 WO2007073096 A1 WO 2007073096A1 KR 2006005603 W KR2006005603 W KR 2006005603W WO 2007073096 A1 WO2007073096 A1 WO 2007073096A1
Authority
WO
WIPO (PCT)
Prior art keywords
momordicae semen
gastritis
extract
momordica saponin
damage
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/KR2006/005603
Other languages
English (en)
French (fr)
Inventor
Bong Cheol Kim
Joo Hyon Kim
Se Jun Yun
Eun Jung Noh
Gi Uk Jang
Chang-Kyun Han
Yong-Baik Cho
Wie-Jong Kwak
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SK Chemicals Co Ltd
Original Assignee
SK Chemicals Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from KR1020050126302A external-priority patent/KR20070065652A/ko
Priority claimed from KR1020060128138A external-priority patent/KR101132730B1/ko
Priority to US12/096,881 priority Critical patent/US20090004309A1/en
Application filed by SK Chemicals Co Ltd filed Critical SK Chemicals Co Ltd
Priority to BRPI0620129-6A priority patent/BRPI0620129A2/pt
Priority to EP06835307A priority patent/EP1962865A4/en
Priority to AU2006328064A priority patent/AU2006328064B2/en
Priority to JP2008547108A priority patent/JP5231244B2/ja
Priority to CN2006800482510A priority patent/CN101340920B/zh
Publication of WO2007073096A1 publication Critical patent/WO2007073096A1/en
Anticipated expiration legal-status Critical
Priority to US12/857,035 priority patent/US8158168B2/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Definitions

  • the gastric mucosal layer which protects the stomach can be easily damaged by
  • NSAID non-steroidal anti-inflammatory drugs
  • bacteria such as aspirin
  • duodenum which is in direct contact with the stomach may get inflammation or ulcer because of the exposure to similar factors.
  • H2 antagonists and proton pump inhibitors for gastritis and gastric ulcer are H2 antagonists and proton pump inhibitors
  • gastric acid secretion inhibitors have a drawback that the condition recurs when the
  • the mucosal protectant which promotes the regeneration of the mucosal tissue
  • treatment using an animal model is to introduce damage on the gastric mucosa by
  • NSAID non-steroidal anti-inflammatory drugs
  • Stillen® by Dong-A Pharmaceutical.
  • the Momordicae semen used in the present invention is a ripe seed of Momordica
  • the Momordicae semen extract is known to contain sterol, oleanolic
  • an object of the present invention is to provide a drug for the
  • the present invention relates to a drug for the prevention and treatment of
  • gastritis or gastric ulcer comprising Momordicae semen extract as an active ingredient.
  • the present invention also relates to a drug for the prevention and treatment of
  • momordica saponin I which is represented by
  • the present invention relates to a drug comprising Mornordicae semen extract
  • NSAID drugs such as diclofenac and good inhibition activity against the secretion
  • the Momordicae semen extract of the present invention is obtained by extracting
  • C 1 -C 6 alcohol is C 1 -C 6 alcohol, more preferably, methanol, ethanol, butanol, etc.
  • the Momordicae semen extract is lyophilized to obtain the extract in powder form.
  • this extract is expected to be very useful as a
  • momordica saponin I of the present invention can be efficiently and efficiently
  • the polar solvent distilled water or alcohol solution may be used.
  • distilled water distilled water or alcohol solution
  • the alcohol is a CI-CO alcohol, more preferably, methanol, ethanol, butanol, etc.
  • column chromatography may be performed to obtain momordica saponin I with better purity. More specifically, a chromatography column is
  • momordica saponin I is a good candidate for the drug for the
  • the Momordicae semen extract or momordica saponin I of the present invention is the Momordicae semen extract or momordica saponin I of the present invention.
  • saponin I of the present invention at a proportion of 2-10 to 1.
  • the active ingredient may be used either in itself or after mixing with a
  • Momordicae semen extract or momordica saponin I of the present invention may vary
  • administration time As a general rule, about 0.1-10 mg per 1 kg of body weight is preferable for the
  • the drug in the unit dosage form may be any drug in the unit dosage form.
  • octadecylsilylated silica resin (YMC*GEL ODS-A 12nm, S-150 m). The amount
  • Momordica saponin I was isolated from the 70 % (v/v) aqueous methanol
  • a rat model test was performed using 100 % ethanol as stomach damage
  • Stillen artificialemisia extract, Dong-A Pharmaceutical
  • Stillen artificialemisia extract, Dong-A Pharmaceutical
  • the damage of the stomach was categorized into flare, congestion, hemorrhage,
  • a rat model test was performed using 100 % ethanol as stomach damage
  • the momordica saponin I isolated in Preparative Example 5 was dissolved in 0.5 % aqueous carboxymethyl cellulose solution to 2 mg/mL and was
  • Mucosta (rebamipide, Korea Otsuka Pharmaceuticals)
  • momordica saponin I had superior effect of preventing the
  • NSAID anti-inflammatory drug
  • Stillen artificialemisia extract
  • test drug were dissolved in 0.5 % aqueous carboxymethyl cellulose solution to 10
  • momordica saponin I was orally administered at a dosage of 20 mg/kg and the
  • control drug Mucosta was orally administered at a dosage of 100 mg/kg. 4 hours
  • SPF pathogen free male Sprague-Dawley rats were purchased from Charles River.
  • momordica saponin I were administered at dosages of 5, 15 and
  • gastric juice taken from the stomach was diluted 10 times with distilled water to obtain a 5 mL sample.
  • the pH of the diluted gastric juice was measured with a
  • gastric juice and thus can be useful in treating gastritis or gastric ulcer.
  • Example 7 Acute toxicity test for oral administration of Momordicae semen extract
  • Acute toxicity test was performed as follows using 6- week-old specific pathogen
  • Preparative Example 1 was orally administered once at a dosage of 1
  • the Momordicae semen extract of the present invention showed no toxicity in all rats up to the dosage of 2,000 mg/kg and was proved to be a safe
  • LD50 minimum oral administration lethal dose
  • Example 8 Acute toxicity test for oral administration of momordica saponin I in
  • Acute toxicity test was performed as follows using 6-week-old specific pathogen
  • Example 5 was orally administered once at a dosage of 400 mg/kg. Survival,
  • momordica saponin I of the present invention showed no toxicity in all rats up to the
  • lethal dose 400 mg/kg or larger.
  • magnesium stearate (2 mg), microcrystalline cellulose (50 mg), sodium starch
  • glycolate 25 mg
  • cornstarch 113 mg
  • anhydrous ethanol anhydrous ethanol (adequate).
  • the momordica saponin I of the present invention was prepared into tablet for
  • cornstarch (113 mg), anhydrous ethanol (adequate).
  • the Momordicae semen extract of the present invention was prepared into
  • composition Momordicae semen extract (5 g), cetyl palmitate (20 g), cetanol (40 g), stearyl
  • the Momordicae semen extract of the present invention was prepared into
  • the Momordicae semen extract of the present invention was prepared into a
  • composition 2 Momordicae semen extract (0.8 g), propylene glycol (1.6 g), liquid paraffin (0.8 g),
  • the momordica saponin I of the present invention was prepared into a

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Steroid Compounds (AREA)
PCT/KR2006/005603 2005-12-20 2006-12-20 Anti-gastritis and anti-ulcer agent containing momordicae semen extract and momordica saponin i isolated from the same Ceased WO2007073096A1 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
CN2006800482510A CN101340920B (zh) 2005-12-20 2006-12-20 包含木鳖子种子提取物和从相同种子中分离得到的木鳖子皂苷ⅰ的抗胃炎和抗溃疡药剂
JP2008547108A JP5231244B2 (ja) 2005-12-20 2006-12-20 胃炎または胃潰瘍の予防及び治療に有用なモクベツシ抽出物及びこれから分離されたモモルディカ・サポニンｉ
US12/096,881 US20090004309A1 (en) 2005-12-20 2006-12-20 Anti-Gastritis and Anti-Ulcer Agent Containing Momordicae Semen Extract and Momordica Saponin I Isolated From the Same
BRPI0620129-6A BRPI0620129A2 (pt) 2005-12-20 2006-12-20 droga para prevenção e tratamento de gastrite ou úlcera gástrica
EP06835307A EP1962865A4 (en) 2005-12-20 2006-12-20 ANTI-GASTRITIS AND ANTI-ULCERE AGENT CONTAINING AN EXTRACT OF MOMORDICAE SEMEN AND SAPONIN I OF MOMORDICA ISOLATED FROM THE SAME EXTRACT
AU2006328064A AU2006328064B2 (en) 2005-12-20 2006-12-20 Anti-gastritis and anti-ulcer agent containing Momordicae semen extract and momordica saponin I isolated from the same
US12/857,035 US8158168B2 (en) 2005-12-20 2010-08-16 Anti-gastritis and anti-ulcer agent containing Momordicae semen extract and momordica saponin I isolated from the same

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
KR10-2005-0126302 2005-12-20
KR1020050126302A KR20070065652A (ko) 2005-12-20 2005-12-20 위염 예방 및 치료에 유용한 목별자 추출물
KR10-2006-0128138 2006-12-14
KR1020060128138A KR101132730B1 (ko) 2006-12-14 2006-12-14 위염 또는 위궤양 예방 및 치료에 유용한 모모르디카사포닌ｉ

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US12/096,881 A-371-Of-International US20090004309A1 (en) 2005-12-20 2006-12-20 Anti-Gastritis and Anti-Ulcer Agent Containing Momordicae Semen Extract and Momordica Saponin I Isolated From the Same
US12/857,035 Division US8158168B2 (en) 2005-12-20 2010-08-16 Anti-gastritis and anti-ulcer agent containing Momordicae semen extract and momordica saponin I isolated from the same

Publications (1)

Publication Number Publication Date
WO2007073096A1 true WO2007073096A1 (en) 2007-06-28

Family

ID=38188807

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2006/005603 Ceased WO2007073096A1 (en) 2005-12-20 2006-12-20 Anti-gastritis and anti-ulcer agent containing momordicae semen extract and momordica saponin i isolated from the same

Country Status (7)

Country Link
US (2) US20090004309A1 (enExample)
EP (1) EP1962865A4 (enExample)
JP (1) JP5231244B2 (enExample)
AU (1) AU2006328064B2 (enExample)
BR (1) BRPI0620129A2 (enExample)
RU (1) RU2429000C2 (enExample)
WO (1) WO2007073096A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009054662A3 (en) * 2007-10-22 2009-06-11 Sk Chemicals Co Ltd Wound-healing agent containing momordicae semen extract
US8071844B1 (en) 2007-09-13 2011-12-06 Nutritional Health Institute Laboratories, Llc Cultivated momordica species and extract thereof

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8877259B2 (en) 2012-02-09 2014-11-04 Mary Kay Inc. Cosmetic formulation

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR930021192A (ko) * 1992-04-11 1993-11-22 이형주 생약함유 화장수 및 그 제조방법
KR950029342A (ko) * 1994-04-21 1995-11-22 이형주 생약함유 미용비누 및 그 제조방법
KR20030021714A (ko) * 2001-09-07 2003-03-15 에스케이케미칼주식회사 독성이 없이 추출된 생약추출물이 복합처방된 생약조성물과 그 제조방법

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR0181751B1 (ko) 1994-12-30 1999-05-01 유충식 위장질환 치료제용 쑥추출물
JPH1059858A (ja) 1996-08-21 1998-03-03 Res Inst For Prod Dev 抗糖尿病剤
JPH11302180A (ja) * 1998-04-16 1999-11-02 Joji Yamahara 抗潰瘍剤
CN1100554C (zh) * 1999-01-19 2003-02-05 刘明堂 一种根治胃下垂的中成药
EP1255566A2 (en) * 2000-02-04 2002-11-13 Seo Hong Yoo Preparation of aqueous clear solution dosage forms with bile acids

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR930021192A (ko) * 1992-04-11 1993-11-22 이형주 생약함유 화장수 및 그 제조방법
KR950029342A (ko) * 1994-04-21 1995-11-22 이형주 생약함유 미용비누 및 그 제조방법
KR20030021714A (ko) * 2001-09-07 2003-03-15 에스케이케미칼주식회사 독성이 없이 추출된 생약추출물이 복합처방된 생약조성물과 그 제조방법

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP1962865A1 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8071844B1 (en) 2007-09-13 2011-12-06 Nutritional Health Institute Laboratories, Llc Cultivated momordica species and extract thereof
WO2009054662A3 (en) * 2007-10-22 2009-06-11 Sk Chemicals Co Ltd Wound-healing agent containing momordicae semen extract
JP2011510912A (ja) * 2007-10-22 2011-04-07 エスケー ケミカルズ カンパニー リミテッド ラカンカ抽出物含有創傷治癒剤

Also Published As

Publication number Publication date
US20090004309A1 (en) 2009-01-01
US8158168B2 (en) 2012-04-17
RU2008129710A (ru) 2010-01-27
US20100310687A1 (en) 2010-12-09
AU2006328064B2 (en) 2012-11-15
BRPI0620129A2 (pt) 2011-11-01
EP1962865A1 (en) 2008-09-03
EP1962865A4 (en) 2010-04-28
RU2429000C2 (ru) 2011-09-20
JP2009520020A (ja) 2009-05-21
JP5231244B2 (ja) 2013-07-10
AU2006328064A1 (en) 2007-06-28

Similar Documents

Publication Publication Date Title
Bopana et al. Asparagus racemosus—Ethnopharmacological evaluation and conservation needs
JP2006510592A (ja) スイカズラ（ＬｏｎｉｃｅｒａｊａｐｏｎｉｃａＴｈｕｎｂ．）茎の活性成分の抽出および精製方法、その消炎鎮痛剤への用途
WO2021179711A1 (zh) 一种从金钗石斛中提取化合物的工艺及应用
KR101045368B1 (ko) 베타닌을 유효성분으로 포함하는 위장질환 예방 또는 치료용 조성물
US8158168B2 (en) Anti-gastritis and anti-ulcer agent containing Momordicae semen extract and momordica saponin I isolated from the same
CN102875615B (zh) 大麻药苷a和大麻药总皂苷的提取方法及其应用
KR101346066B1 (ko) 백합나무 수피 추출물을 유효 성분으로 함유하는 약학적 조성물
CN101861158A (zh) 含有木鳖子提取物的伤口愈合剂
CN101340920B (zh) 包含木鳖子种子提取物和从相同种子中分离得到的木鳖子皂苷ⅰ的抗胃炎和抗溃疡药剂
JP2009520020A5 (enExample)
KR101132730B1 (ko) 위염 또는 위궤양 예방 및 치료에 유용한 모모르디카사포닌ｉ
Chattopadhyay et al. Preliminary phytochemical screening and in vitro evaluation of anthelmintic activity of leaves and stem bark of Mangifera Indica L.(Anacardiaceae)
CN114767760B (zh) 一种具有保肝作用的组合物
KR20150105154A (ko) 백년초 추출물을 포함하는 위장질환 치료용 약제학적 조성물
KR20200052770A (ko) 결명자 추출물을 포함하는 위장질환 예방 및 치료용 조성물
KR101028865B1 (ko) 무로부터 설포라펜을 분리하는 방법 및 이의 용도
Mohammed et al. Antiulcerogenic activities of Agelanthus dodoneifolius leaf against acetyl salicylate and ethanol induced ulceration in rats
Yuzurihara et al. Effect of Saiboku‐to, an Oriental Herbal Medicine, on Gastric Lesion Induced by Restraint Water‐immersion Stress or by Ethanol Treatment
EP0142036A1 (en) Pharmaceutical agent for ulcers of the gastro-intestinal tract
Sheela et al. Antiulcer activity of Cayratia pedata, Enicostemma axillare and Terminalia chebula on ethanol induced Albino Wister rats
Shukla et al. Lack of hypoglycemic activity in total flavonoid fraction of Wrightia tinctoria on alloxan induced hyperglycemia
CN116549551A (zh) 芦荟全叶粉或其活性成分在制备治疗慢性萎缩性胃炎药物中的应用
WO2011120118A1 (pt) Processo de obtenção de micropartículas matriciais de copaífera langsdorffii (partes aéreas) e isolamento dos princípios ativos; micropartículas e compostos assim obtidos, com atividade antilitiásica (cálculo renal), analgésica, anti-espasmódica, anti-inflamatória, diurética e anti-séptica, suas formulações, produtos e usos.
Alkali et al. Antiulcerogenic activities of Agelanthus dodoneifolius leaf against acetyl salicylate and ethanol induced ulceration in rats
Nagul Evaluation Of Anti-Ulcer Activity of Alcoholic Extract of Hibiscus Rosa Sinesis In Rats.

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200680048251.0

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2006328064

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 5208/DELNP/2008

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2008547108

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2006835307

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2006328064

Country of ref document: AU

Date of ref document: 20061220

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2008129710

Country of ref document: RU

WWE Wipo information: entry into national phase

Ref document number: 12096881

Country of ref document: US

ENP Entry into the national phase

Ref document number: PI0620129

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20080620